Purpose: Multiple myeloma is an incurable malignant plasma cell disease characterized by survival ranging from several months to more than 15 years. Assessment of risk and underlying molecular heterogeneity can be excellently done by gene expression profiling (GEP), but its way into clinical routine is hampered by the lack of an appropriate reporting tool and the integration with other prognostic factors into a single "meta" risk stratification.
Introduction
Multiple myeloma is an incurable malignant disease of clonal plasma cells which accumulate in the bone marrow causing clinical signs and symptoms related to the displacement of normal hematopoiesis, bone marrow neovascularization, formation of osteolytic bone lesions, and production of monoclonal protein (1, 2) . On a molecular level, multiple myeloma is characterized by a pronounced heterogeneity in terms of chromosomal aberrations and altered gene expression (2) (3) (4) (5) . This molecular heterogeneity is thought to transmit into survival ranging from months to 15 years or more (6) (7) (8) . Within this time, almost all patients with myeloma relapse, necessitating a careful planning of subsequent treatment regimen and an appropriate selection of (further) compounds to be used, for example, as an individualized or add-on treatment.
Gene expression profiling (GEP) is an ideal tool to assess this molecular heterogeneity in terms of gene expressionbased classifications of distinct biologic entities (9) (10) (11) (12) (13) . Importantly, prognostic groups with highly different survival have been defined, namely, using the gene expressionbased risk scores of the University of Arkansas for Medical Sciences (UAMS; Little Rock, AR) and the Intergroup Francophone du My elome (IFM) as well as a gene expression-based proliferation index (GPI; refs. 14-16). Moreover, GEP allows the assessment of target gene expression, for example, aurora kinase A (AURKA), fibroblast growth factor receptor 3 (FGFR3), insulin-like growth factor 1 receptor (IGF1R; refs. 3, 5, 9) , for which clinical inhibitors are available (e.g., VX-680, CHIR-258, NVP-AEW541; refs. 3, 5, 17) , and potential targets of vaccination strategies (e.g., MAGEA3; refs. 18, 19) . GEP can currently be done in about 80% of therapy requiring patients in terms of available material, that is, purified myeloma cells. It has been done on large cohorts of patients within clinical trials, but except in a very limited number of cancer centers, only retrospectively. This is surprising in that the prerequisites, that is, purification of malignant plasma cells can be done at most academic institutions (20) . The same holds true for GEP using core facilities or commercial service providers. Thus, the main difficulty remaining for prospective use of GEP in clinical routine is an affordable (i.e., academic) reporting tool giving quality-controlled, validated, and clinically digestible information that can be used by clinicians without extensive bioinformatics training. We present here such a gene expression-based report (GEP-R) including molecular classification, risk stratification, and assessment of target gene expression. Within the GEP-R, an implemented metascore integrates current expressionbased and conventional prognostic factors into one superior prognostic classification. The GEP-R is a noncommercial software framework adaptable to other cancer entities that can be downloaded at http://code.google.com/p/gep-r. A "LiveDVD" for testing without the need to install the program is available at https://gliserv.montp.inserm.fr (see Results for details).
Materials and Methods

Software design
The GEP-R software is developed within the open-source software environments R (21) and Bioconductor (22) using a graphical user interface (GUI; see Supplementary Fig. S1 ) based on the gWidgets package (23) . It processes a single Affymetrix U133 Plus 2.0 .CEL file using a "documentation by value (docval)-strategy" (24) modified for GC-RMA preprocessing (available at http://code.google.com/p/ gep-r). This allows using preprocessing information of our reference cohort of 262 quality-controlled myeloma samples (E-MTAB-372) and thus generated thresholds to be applied to a subsequent microarray, a prerequisite for prospective use of a gene expression report based on GC-RMA preprocessed data. A detailed description of the GUI and how to use it is provided in the Supplementary Materials and Methods.
Quality control
Quality control (QC) implemented is based on the Bioconductor packages affyQCReport (25) , affyPLM (26) (27) (28) , simpleaffy, and yaqcaffy (29) adapted for GC-RMA preprocessing and PANP-based (30) assessment of presence/ absence of gene expression. To limit computation time, 6 samples from the reference cohort have been chosen randomly as QC reference.
Sample validation
Using prediction analysis for microarrays [PAM; (31) ], predictors for sex, the IgL-(lambda and kappa), and IgHtype (IgA, IgG, IgD) have been implemented using one part of the reference cohort as training set and the other one as test set. For further validation, the UAMS total therapy 2 (TT2) cohort (GSE24080) and the Multiple Myeloma Research Consortium data (MMRC; www.broadinstitute. org/mmgp/home) were used.
Risk stratification
Two gene expression-based risk scores and a risk delineating GPI are implemented: (i) The IFM 15-gene model (15) developed on one-channel DNA Unit e Mixte de G enomique du Cancer (UMGC) microarrays transferred to respective genes represented on Affymetrix U133 Plus 2.0 arrays. Cutoff points for low/high risk have been generated on the reference cohort defining the 25% of patients with the highest risk score as high risk, showing comparable results with the original publication (15) . (ii) The UAMS 70-gene risk score was calculated as published on MAS5 preprocessed data using published cutoff points (14) . (iii) The GPI (16) with cutoff values for low/medium/high risk was regenerated on the reference cohort. The attribution of the TT2 cohort to the respective risk stratification can be found in Supplementary Table S1 .
Assessment of gene expression
Expression height and presence/absence of expression by PANP (30) is assessed for (i) potential "target genes" for whose products clinical grade inhibitors exist (currently AURKA, FGFR3, and IGF1R), (ii) potential vaccination targets, and (iii) genes frequently aberrantly (i.e., not expressed in normal plasma cells) or differentially expressed in myeloma (i.e., expression value greater/lower than the
Translational Relevance
Multiple myeloma is an example for a cancer entity characterized by a pronounced molecular heterogeneity, transmitting into survival times ranging from months to more than 15 years. Gene expression profiling is an ideal tool to assess this heterogeneity in terms of gene expression-based biologic classifications and prognosis and allows assessment of target genes. However, it is almost never used prospectively in clinical routine, mainly due to the lack of an academic reporting tool giving quality controlled, validated, and clinically digestible information.
We present here a gene expression-based report. The gene expression-based report is a customizable opensource software that can be adapted to novel parameters or other cancer entities. It includes molecular classification, risk stratification, and assessment of target gene expression. Furthermore, the HM-metascore combines validated conventional and expression-based risk factors into one superior metascore, thus helping to overcome the confusing and increasing multitude of prognostic factors.
respective value from normal plasma cells AE 3 SDs). In the report's appendix, values are put in comparison to normal plasma cells (n ¼ 10) and myeloma cell samples (n ¼ 262; Supplementary Fig. S2 ).
Gene expression-based classification of myeloma
The following 3 gene expression-based classifications of multiple myeloma are assessed: (i) The TC classification by Bergsagel and colleagues (10, 11) derived on Hu95Av2 DNA microarrays (Affymetrix) using MAS5 preprocession was implemented on U133 2.0 (Affymetrix) DNA microarrays as described by Chng and colleagues (32) . (ii) The molecular classification of multiple myeloma (9): We first carried out an unsupervised clustering of the reference cohort based on the 700 genes published (being de facto 687 genes). The resulting 7 clusters could be attributed to the 7 groups of the molecular classification. A "myeloid group" could not be delineated (see Results). A PAM-based predictor using these 687 genes was calculated on 162 patients of the reference cohort and validated on 100 patients, respectively. (iii) The EC classification (12) was reimplemented on the reference cohort and assessed by a PAM predictor consisting of 188 genes. The attribution of the TT2 patients to the respective gene expression-based classifications can be found in Supplementary Table S1 .
Chromosomal aberrations-presence of t(4;14)
The presence of a translocation t(4;14) has been assessed by interphase FISH as previously published (16) and a PAMbased predictor using parts of the reference cohort as training set and the other part as test set has been generated (36 genes).
Calculation of the HM-metascore
The calculation of the HM-metascore is described in the Results section (see later).
Results
GEP-R
After input of patient information (e.g., sex, IgH/L-type), the GEP-R software carries out MAS5 and GC-RMA preprocessing as detailed above and subsequently applies the following: (i) quality control of gene expression data, (ii) sample validation, (iii) gene expression-based classification, (iv) risk stratification, and (v) target assessment. The physician preparing the report comments respective findings within the report in an editable text field. A PDF file containing the final report is generated by the software using the Sweave package (33) . The GEP-R consists of the following 2 parts: (i) the report given to the treating physician ( Fig. 1) and (ii) an appendix containing detailed quality control and validation information, as well as details of the assessment of gene expression ( Supplementary Fig. S2 ). Analyzing a .CEL file with GEP-R takes about 20 minutes on a standard computer (2þ GB RAM required). The GEP-R runs on Linux, MacOS, and Windows systems. Optionally, results and gene expression data can be written to a PostgreSQL database using PostgreSQL through pgUtils (34) and maDB (35) packages, provided a running postgreSQL database. For metascore generation (HM-score, see below), the patient's International Staging System (ISS) stage needs to be entered.
Description of the GUI
The GEP-R GUI is divided into 2 parts ( Supplementary  Fig. S1 ). Left part: Within the left part of the GUI, the user (i) loads an Affymetrix U133 Plus 2.0 raw file into the software, starts the analysis, can save or load previous analyses, and creates the GEP-R as a PDF document. The user enters (ii) patient-and (iii) sample-specific data (e.g., patient name, IgH-/IgL-type) necessary for identification and validation. Afterward, the .CEL file is analyzed by the GUI calling an Rscript carrying out MAS5 and GC-RMA preprocessing using preprocessed information of the reference cohort. The user here (iv) comments the parameters within the report and (v) includes a concluding statement. Right part: here, the results of the analysis are presented in 3 tabs for (i) parameters analyzed (e.g., risk scores), (ii) quality control parameters and plots, and (iii) identity control parameters that appear if entered patient data do not match predicted values (e.g., IgH-type), or a data field misses an entry (Supplementary Figs. S2 and S3). A detailed description of the GUI and how to use it is included in the Supplementary Materials and Methods.
Exemplary report
An example of a GEP-R (final PDF-based patient report given to clinicians and patients) is depicted in Fig. 1 , the full report including the appendix in Supplementary Fig. S2 .
Quality control
QC metrics assessed are average background, percentage of present calls as detected by the PANP algorithm, 3 0 , mid and 5 0 expression of b-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Six plots allow the assessment of reproducibility, QC statistics, spike-in performance, normalized unscaled standard error (NUSE), relative log expression (RLE), pseudo images, for example, allowing the detection of artifacts, and RNA degradation ( Supplementary Fig. S3 ). Supplementary Table S2 depicts samples from the initial cohort of 280 patients failing these criteria. In all, 18 samples (6.4%) failed in at least one criterion and were excluded. One criterion was failed by 10 (3.5%), 3 criteria by additional 4 (1.4%), and 3 or more by 4 (1.4%) further samples, respectively.
Validation
The GEP-R software compares predicted sex, IgH-, and IgL-type with user-entered patient information and gives a warning in case of inconsistency. For prediction errors, see Supplementary Table S3 . Predictors were validated on the UAMS TT2 cohort and the MMRC data set (Supplementary  Table S3 ).
Risk stratification
Using the GEP-R-based assessment, the gene expressionbased risk scores of the UAMS and IFM significantly delineate a high-risk population of 29.2% and 22.9% of patients with myeloma, respectively. The same holds true for the GPI significantly delineating 6.3%, 47.9%, and 45.8% of patients as high, intermediate, and low risk ( Supplementary  Fig. S4 ). The risk stratification according to the UMAS 70-gene score for the UAMS patients is available as Supplementary Table S1 .
Assessment of target gene expression
On our reference cohort, the assessed target genes AURKA, IGF1R, and FGFR3 are expressed in 29.3%, 28.2%, and 13.4% of myeloma samples, respectively. Expression of each gene is significantly associated with adverse survival on our cohort (Supplementary Fig. S4 ). For the reporting, see Supplementary Figs . S1 and S2.
Gene expression-based classification of myeloma
The TC classification is implemented as suggested by the authors (ref. 32; see above). Grouping is validated by published data of the TT2 data set (Supplementary Table   S1 ). The EC classification implemented as stated above can be predicted with an overall error rate of 3% (Supplementary Table S3B ). In contrast, grouping according to the "molecular classification" proposes a problem as there is no clear delineation algorithm of the so-called "myeloid group" published. Nevertheless, the molecular classification (7 groups, without the "myeloid group") can be predicted with an overall error rate of 11%. For details, see Supplementary Table S3B . The overlap of our prediction with the grouping according to Zhan and colleagues (9) is visualized in Supplementary Table S1 .
Chromosomal aberrations-presence of t(4;14)
The presence of a translocation t(4;14) can be assessed using a PAM-based predictor without error (Supplementary  Table S3C ). Its expression is significantly associated with adverse prognosis (Supplementary Fig. S4 ).
Building a metascore including current prognostic information
To integrate depicted expression-based and clinical prognostic factors within one prognostic (meta-) score (HM-score), a weight of 0, 0.5, or 1 is given for each of the named prognostic factors. The HM-score is calculated as the sum over these weights for gene expression-based assessment of risk (0, 0.5, 1 for none, one, or both of the UAMS-and IFM-scores depicting high risk, respectively), proliferation (0, 0.5, 1 for GPI low, median, or high, respectively), ISS (0, 0.5, 1 for ISS stage 1, 2, and 3, respectively), t(4;14) (0 for absence, 1 for presence of the aberration), and expression of prognostically relevant target genes (0 or 1 if none or at least one of the genes AURKA or IGF1R is expressed, respectively). The model delineates 3 significantly different groups of 13.1%, 72.1%, and 14.7% of patients with an HM-score of 0 (none of the risk factors), 0.5-3, and >3, and a 6-year survival rate of 89.3%, 60.6%, and 18.6% of our patients (HM cohort), respectively. It is likewise prognostic for event-free survival (Fig. 2) . The HM-score is validated using published information on the respective parameters on the TT2 cohort ( Fig. 2; refs. 3, 5, 16 ).
Downloadable version and files
The GEP-R software is open-source and can be downloaded at http://code.google.com/p/gep-r. The source code can be freely modified and customized to user requirements. The GEP-R is currently validated for use of Affymetrix gene expression data obtained by double amplification protocol. A "LiveDVD" for direct testing of the report containing 3 exemplary .CEL files of patients with myeloma is available at https://gliserv.montp.inserm.fr (user: gepr, password: review).
Discussion
In this article, we introduce a reporting tool (GEP-R) allowing automated interpretation of Affymetrix U133 Plus 2.0 gene expression profiles. It enables the prospective use of GEP within clinical routine in terms of molecular classification, risk stratification, and assessment of target genes. This represents the critical first step in a process that will IGF1R) . A, significant delineation of event-free survival (EFS) within our (HM cohort) and the TT2 cohort.
(HM cohort, P < 0.001, low vs. medium, P ¼ 0.02, medium vs. high, P < 0.001; TT2 cohort, P < 0.001, low vs. medium, P < 0.001, medium vs. high, P < 0.001, respectively). B, significant delineation of overall survival (OS; HM cohort, P < 0.001, low vs. medium, P ¼ 0.03, medium vs. high, P < 0.001; TT2 cohort, P < 0.001, low vs. medium, P ¼ 0.006, medium vs. high, P < 0.001, respectively).
eventually allow for reproducible approaches and a standardization of the analyses across different centers as well as for personalized treatment.
In 2009, the International Myeloma Working Group stated: "Our group also recognizes that the greatest prognostic ability for multiple myeloma resides in the comprehensive analysis of GEP. At a minimum, all clinical trials should consider incorporation of GEP into the correlative science studies to identify subgroups of high-risk disease. We also propose that methodology to include GEP into the clinical testing is urgently needed and methods for implementation should be identified" (16) . In the following, we discuss use, interest in, and clinical applicability of GEP and the GEP-R, respectively.
Three gene expression-based classifications delineate molecular groups in myeloma: The "molecular classification" based on differential gene expression in which 3 of 7 groups ("proliferation," MAF expression, MMSET overexpression) show different survival (9); the TC classification based on translocations and D-type cyclin without prognostic relevance (10, 11) and the EC classification based on chromosomal aberrations and resulting changes in gene expression with only 1 of 4 groups [t(4;14) and FGFR3-expression] showing adverse prognosis (12, 13) . Biologic classifications likely remain relatively stable in contrast to prognostic factors prone to change with different treatment schedules (see below).
The translocation t(4;14) represents a specific disease entity and is an independent risk factor despite conventional or high-dose treatment (36) (37) (38) (39) (40) (41) . Treatment with bortezomib or lenalidomide containing regimen seems to at least lessen the negative prognostic impact of this aberration (6, (42) (43) (44) (45) and can thus be selected. t(4;14) is present in 13% of patients in our reference cohort and can be predicted without error by GEP (Supplementary Table  S2C ).
Gene expression-based risk stratification is applied using the following 4 different strategies: (i) To investigate differences in survival between molecular groups (see above). (ii) To surrogate biologic variables associated with prognosis, for example, here proliferation as strong adverse prognostic factor in myeloma (46) (47) (48) (49) by GPI (ref. 16 ; Supplementary  Fig. S4 ). (iii) To build a score over a set of genes associated with survival, exemplified by the high-risk scores of the UAMS (70 genes) and the IFM (15 genes; refs. 14, 15). Both scores allowed delineating a group of patients (13% and 25%, respectively) with very adverse prognosis in the IFM and total therapy 2-data set (not including bortezomib), whereas in the total therapy 3-cohort (including bortezomib), only the UAMS-score remains significant (14, 15) . In relapsed patients treated with bortezomib within the APEX, SUMMIT, and CREST trial (n ¼ 188), both scores significantly delineate different outcome, in patients treated with dexamethasone (n ¼ 76), only the UAMS score. In our cohort of patients, 32.4% and 25.2% of patients are delineated to be of "high risk." As implemented in the GEP-R, 2 groups of patients with significantly different survival can be delineated on our cohort (Supplementary Fig. S4 ). (iv) To assess the presence of expression of a gene representing a potential target and investigate its prognostic relevance, exemplified by AURKA (3), IGF1R (5), and FGFR3 (12, 13) in the current version of the GEP-R (Supplementary Fig.  S4 ). As these genes are only expressed in 13% to 28% of patients, they are ideal targets for personalized treatment, for example, add-on for current induction treatment regimen, and respective clinical trials are in preparation. GEP likewise allows the screening for a large number of immunotherapeutic targets, for example, cancer testis antigens (18, 50) , exemplified by MAGEA3 (18, 19) . In both cases GEP-R easily allows assessment of expression of such target genes, thus enabling personalized treatment.
A sufficient number of malignant plasma cells for GEP at a purity of 80%, that is, 5 Â 10 4 to 5 Â 10 5 cells if a double amplification protocol and Affymetrix U133 2.0 arrays are used, can be obtained in about 80% of therapy requiring patients with myeloma at most academic institutions (20) , as can be GEP. As global GEP allows simultaneous assessment of (almost) all genes without any need for preselection, novel risk stratifications and target genes as well as predictors for response can be applied using existing expression data and easily be included in the GEP-R software framework.
A pressing practical problem for clinical risk assessment is how to integrate the various risk factors into a single clear message given to physicians and patients. The HM-score here combines main current expression-based and conventional prognostic factors and prognostically relevant targetable genes reported in the GEP-R delineating 3 groups of patients with highly significantly different event-free and overall survival (Fig. 2) .
Therefore, the GEP-R here allows overcoming the main difficulty remaining for prospective use of GEP in clinical routine: an affordable reporting tool giving quality-controlled, validated, and clinically digestible information that can be used by clinicians without extensive bioinformatics training. It is used by the Universities of Heidelberg and Montpellier in clinical routine as well as within the GMMG-MM5 multicenter trial of the German-Speaking Myeloma Multicenter Group (GMMG) and will be validated prospectively in 600 evaluable patients within a multicenter trial funded by the German Federal Ministry of Education and Research.
In conclusion, gene expression profiling using GEP-R allows prospective reporting of molecular classifications, risk, and therapeutic targets to clinicians in clinical routine in a digestible manner and thus represents a major step in translational oncology. It will foster carrying out clinical trials using risk-adapted and personalized treatment strategies.
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